Results 121 to 130 of about 206,964 (305)
The Application of Clinical Genetics, 2019 Mohanad Yasir Al-Radeef,1 Hayder Adnan Fawzi,2 Ali Abdulmajid Allawi31Department of Clinical Pharmacy, College of Pharmacy, Tikrit University, Tikrit, Iraq; 2Department of Clinical Pharmacy, Baghdad Medical City Hospital, Baghdad, Iraq; 3Department of ...
Al-Radeef MY, Fawzi HA, Allawi AA
doaj
ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki +11 more
wiley +1 more source
Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk, 2021 In December 2019, a new type of coronavirus called COVID-19 was identified as an unknown cause of pneumonia in Wuhan, China. The pandemic virus was transmitted to humans from a type of seafood that could spread significantly among humans in a short time.
Seyedeh Sara Azadeh +1 more
doaj
Hepatic Mitochondrial Renin-Angiotensin Systems
, 2015 Introduction: The circulating renin-angiotensin system (RAS) was originally described as a key endocrine regulator of intravascular homeostasis; however, the existence of a local (tissue) RAS has become increasingly reported in a variety of tissues ...
Skipworth, JRA
core
ACE-inhibition prevents postischemic coronary leukocyte adhesion and leukocyte-dependent reperfusion injury [PDF]
, 1997 Objective: Polymorphonuclear leukocytes (PMN), retained in the microvascular bed, can contribute to postischemic myocardial reperfusion injury. Since a beneficial effect of ACE-inhibition on reperfusion injury has been reported, we investigated the ...
Weber, Christian +6 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro +15 more
wiley +1 more source
Biological and Pharmaceutical Bulletin, 2011 The balance of angiotensin-converting enzyme (ACE) and angiotensin-converting enzyme 2 (ACE2) in high blood pressure variability (BPV) induced cardiovascular hypertrophy remains elusive. The aim of the present work was to investigate expression and activity of ACE and ACE2 in the heart and aorta of sinoaortic denervation (SAD) rats with high BPV and ...
Zhang, Li-Chao +6 more
openaire +2 more sources
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Three angiotensin-converting enzyme inhibitors from Rabdosia coetsa
, 2008 The EtOAc extract of Rabdosia coetsa showed angiotensin-converting enzyme (ACE) inhibitory activity. Bioassay-guided isolation of this extract yielded ethyl caffeate (1), rosmarinic acid (2) and methyl rosmarinate (3), which inhibited ACE activity by 32 ...
Li, QL +6 more
core
ANGIOTENSIN CONVERTING ENZYME INHIBITION ACTIVITY OF DAIDZEIN
, 2014 Daidzein produces antihypertensive and beneficial cardiovascular effects, although the mechanisms for these effects are not known. We examined whether genistein inhibits the in vivo responses to angiotensin I or enhances the responses to bradykinin in ...
Choudhury, Avijit, Pai, K. Vasantkumar
core +1 more source